HENRY SCHEIN INC
Nasdaq: HSIC·Melville, New York·CIK 0001000228
- Price
- $84.96
- Base IV
- $39.74
Valuation snapshot
At $84.96, the price is above even our bull case of $70.44.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $39.74
- 47% of the price · range $13.97–$70.44
- Price vs base case
- 114% above
- $84.96 against $39.74
- Base case · our researched forecast, 2026-11-12See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 3.9% since this valuation was struck on 2026-11-12, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $13.97 to bull $70.44. Values per share.
Price against each value
- Bear case
- $13.97
- Price 508% above
- No growth
- …
- —
- Base case
- $39.74
- Price 114% above
What does Henry Schein do?
Henry Schein distributes medical and dental supplies, equipment, and software to healthcare practitioners and clinics to help them manage inventory and provide clinical care.
It brought in $13.7B of sales in the 12 months to Sep 2026.
Led by Frederick M. Lowery, Chief Executive Officer and Director since 2026. Henry Schein, Inc. Form 8-K – Board appoints Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026
- Industry
- Industrials
- Based in
- Melville, New York
- Trades on
- Nasdaq as HSIC
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 3¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 68¢ of every dollar.
- Making what it sells68¢
- Sales, marketing and admin24¢
- Everything else it takes to operate3¢
- Interest and other costs1¢
- Tax1¢
- Left as profit3¢
Who pays Henry Schein, and for what?
Henry Schein supplies dental and medical practices with everyday products, equipment and repair services. It also sells dental implants and other specialty products, plus software that helps practices run their businesses. It earns revenue when customers buy these products and services.
Dental and medical practices, laboratories, surgery centers, clinics, home health providers and government health facilities pay for its products and services.
Dental merchandise
37%Everyday dental supplies, including infection-control products, filling materials and Henry Schein’s own-brand products.
Dental equipment
14%Dental chairs, imaging and digital equipment, along with installation and repair services.
A-dec 511 dental chairImage: Henry Schein Value-added services
2%Practice financing arranged through third parties, continuing education, consulting and other services.
Medical products
33%Medicines, vaccines, tests, surgical supplies, home health products and equipment.
Specialty products
12%Products Henry Schein makes or markets, including dental implants, materials for rebuilding tissue, braces and products used in root canals and orthopedic surgery.
Technology
5%Software and online services for managing practices, patient records, billing and patient communication.
Ascend by Dentrix practice management softwareImage: Henry Schein One
Where its work physically happens, beyond headquarters:
- Southwestern Distribution Center (AllianceTexas) — Fort Worth, United States. This 811,000 sq ft site is the largest single building in Henry Schein's global network and replaced the Grapevine DC, so its capacity and automation support U.S. distribution volume and margins.
- Denver Distribution Center — Denver, United States. This roughly 624,000 sq ft leased distribution center (lease runs to 2032) is one of the company's largest U.S. hubs for dental and medical consumables in the Northeast and Mid-Atlantic.
- Indianapolis Distribution Center — Indianapolis, United States. Henry Schein calls this one of its five core U.S. distribution centers, handling more than 80,000 SKUs, so it carries a large share of North American distribution volume.
- Jacksonville Distribution Center — Jacksonville, United States. This roughly 212,000 sq ft leased distribution center serves customers in the southeastern U.S. for the Global Distribution and Value-Added Services segment.
- BioHorizons Global HQ and Distribution Center — Birmingham, United States. This site of more than 125,000 sq ft is the global distribution and R&D base for BioHorizons dental implants, a key part of the higher-margin Global Specialty Products segment.
How is the business doing?
Sales grew from $10.1B in 2020 to $13.2B in 2025, about 5% a year.
Running the business leaves about 5¢ of each sales dollar as operating profit, about the same as 5¢ in 2020.
After paying for its upkeep and new investment, it had $559M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Henry Schein says it aims to help health professionals provide better patient care while running their practices efficiently.
“to be trusted advisors and consultants to our customers”
Who is responsible for the plan?
Frederick M. LoweryChief Executive Officer and DirectorLeads Henry Schein as Chief Executive Officer and sits on its Board of Directors. The CEO runs the whole company, which distributes dental and medical products and sells practice technology and value-added services to healthcare practitioners.
Andrea AlbertiniChief Executive Officer, Global Distribution and TechnologyLeads the Global Distribution Group and Technology Group, including dental and medical distribution, the dental lab and prosthetic solutions business, and technology and value-added services. The global distribution business makes most of Henry Schein's revenue by selling consumables, equipment and related services to dental and medical practices.
Roles checked November 12, 2026.
What management says it is working on now:
Grow specialty products, software and services
Management plans to build these businesses through its own investment and acquisitions.
Henry Schein 2025 Form 10-K, Business StrategyImprove distribution
The BOLD+1 plan calls for a more unified distribution operation to improve customer service and efficiency.
Henry Schein 2025 Form 10-K, Business StrategySell more to existing customers
The One Schein approach brings supplies, equipment, specialty products, software and services together so practices can buy more of what they need from the company.
Henry Schein 2025 Form 10-K, Business Strategy and Item 7Expand digital tools
Management plans to improve online purchasing and software for customers while using digital tools to make its own operations more efficient.
Henry Schein 2025 Form 10-K, Business Strategy
- Adjusted earnings per share, Full year 2026
- $5.29 to $5.39
- Henry Schein second-quarter 2026 results and guidance
- Adjusted EBITDA growth, Full year 2026
- Mid to high single digits
- Henry Schein second-quarter 2026 results and guidance
- Annual operating income improvement from cost and efficiency projects, By the end of 2026
- $125 million annual pace
- Henry Schein Q2 2026 earnings call transcript
- Annual operating income improvement from cost and efficiency projects, As projects continue into early 2028
- More than $200 million
- Henry Schein Q2 2026 earnings call transcript
- Share of operating income from faster-growing, higher-margin businesses, By the end of 2027
- More than 50%
- Henry Schein Q2 2026 earnings call transcript
What's changing right now?
Growth is slowing. In Q3 2026 it sold 4% more than a year earlier. The year before, quarters averaged 6%.
Its operating margin is about where it was a year ago, 6¢ per sales dollar.
Since Oct 2026 the share price has fallen 2%, from $86.44 to $84.96.
Recently
November 3, 2026
GAAP operating margin, quarterly changed to 5.6%
HSIC Q3 2026 8-K Ex. 99.1November 3, 2026
Total sales growth, quarterly year-over-year changed to 4.0%
HSIC Q3 2026 8-K Ex. 99.1December 27, 2025
Cash Flows from Operating Activities changed to $712.0M
Henry Schein 2025 Form 10-K Statements of Cash Flows
Coming up
November 3, 2026
Third-quarter results
Henry Schein plans to release results and hold an earnings call, offering an update on sales and its efficiency projects.
Henry Schein third-quarter 2026 earnings call announcementNovember 4, 2026
Chief financial officer transition
Emmanuel Caprais is scheduled to become chief financial officer.
Henry Schein CFO leadership transition announcementBy the end of 2026
Efficiency project milestone
Management expects its cost and efficiency projects to reach a $125 million annual pace of operating income improvement.
Henry Schein Q2 2026 earnings call transcript
Our own estimate moved too: the base case went from $55.95 to $39.74 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Supplier interruptions
Henry Schein buys much of what it sells from other companies, often without long-term contracts. If a key product becomes unavailable, sales and customer relationships could suffer.
From the company's own filingsWould hit how fast sales growHenry Schein 2025 Form 10-K, Item 1A: Risk Factors
Strong competition and larger buyers
Other distributors, manufacturers and online sellers compete for the same customers. As practices combine into larger groups, those buyers may demand lower prices.
From the company's own filingsWould hit how much of each sale it keepsHenry Schein 2025 Form 10-K, Items 1 and 7
Product and health care rules
The company must meet extensive rules for medicines, medical devices, patient data and reimbursement. Compliance problems or changing rules could delay sales or raise costs.
From the company's own filingsWould hit how much of each sale it keepsHenry Schein 2025 Form 10-K, Items 1 and 1A
Cybersecurity and patient data
A 2023 cyber incident disrupted distribution and was followed by lower sales to some customers. Another breach could interrupt orders or expose sensitive information.
From the company's own filingsWould hit how fast sales growHenry Schein 2025 Form 10-K, Items 1A and 7
Tariffs and insurance coverage
Tariffs could raise product costs, while expected reductions in Medicaid enrollment and funding could reduce demand for covered care and supplies.
From the company's own filingsWould hit how fast sales growHenry Schein 2025 Form 10-K, Item 7: Recent Developments
Growth plan may fall short
The company is investing in specialty products, software and efficiency projects. New products may fail to win customers, and the projects may deliver less benefit than planned.
From the company's own filingsWould hit how much of each sale it keepsHenry Schein 2025 Form 10-K, Item 1A: Risk Factors
Value-Added Services sales fell 4.8% and medical grew only 1.1% in Q3 2026.
From our researchWould hit how fast sales growHSIC Q3 2026 press release
Q3 2026 EPS included a $0.19 per share tariff-refund benefit that will not recur.
From our researchWould hit how much of each sale it keepsHSIC Q3 2026 8-K Ex. 99.1
Is it a good business?
From 2016 to 2025 it earned between 8% and 16% on the capital invested in it, a median of 12%. Its cost of capital in the latest valuation is 7.7%; returns were above it in every one of the 10 years.
From 2016 to 2025 it earned between 11% and 23% on its shareholders' equity, a median of 15%.
Over 10 years its operating margin ranged from 5¢ to 7¢ per sales dollar, a median of 6¢. Gross margin ran from 27¢ to 32¢.
Cost of capital 7.7%
It bought back shares: the count fell 7.0% in a year, so each remaining share owns a slightly bigger slice.
It owes $3.3B more than it holds in cash, about 4.7 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $84.96. Our put its value between $13.97 and $70.44, with $39.74 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $13.97
This scenario assumes Henry Schein's recent sales pickup fades back to the slow pace of 2022 to 2024 and that its cost-cutting does little more than hold profits steady at today's thin levels.
Base case, $39.74
This scenario assumes Henry Schein keeps growing sales a little faster than its slow 2022 to 2024 pace, as in 2025 and 2026, and that its cost-saving program modestly improves its thin profits.
Bull case, $70.44
This scenario assumes Henry Schein returns to the stronger sales growth of early 2026 and that its cost-saving program clearly lifts its historically thin profits.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 114%
For Henry Schein to be worth today's $84.96, sales would need to grow about 14.8% a year. We assume 3.6%. Over the last 5 years, sales grew 2.3% a year.
Or, if sales grow 3.6% as we assume, the price works with a profit margin of 9.6% (we assume 6.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 14.8% a year?
Try your own numbersWe're moderately sure of this range: it scores 57 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $39.74 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average3.6%
- Operating margin6.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$39.74 -53.2%


